

Mohammad Shahnawaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10559681/publications.pdf>

Version: 2024-02-01

21
papers

1,751
citations

516561

16
h-index

794469

19
g-index

22
all docs

22
docs citations

22
times ranked

2328
citing authors

#	ARTICLE	IF	CITATIONS
1	Discriminating $\hat{1}\pm$ -synuclein strains in Parkinson's disease and multiple system atrophy. <i>Nature</i> , 2020, 578, 273-277.	13.7	479
2	Development of a Biochemical Diagnosis of Parkinson Disease by Detection of $\hat{1}\pm$ -Synuclein Misfolded Aggregates in Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2017, 74, 163.	4.5	312
3	Detection of Misfolded $\hat{A}\hat{1}^2$ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer's Disease. <i>Cell Reports</i> , 2014, 7, 261-268.	2.9	154
4	Comparative study of cerebrospinal fluid $\hat{1}\pm$ -synuclein seeding aggregation assays for diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 536-544.	2.2	146
5	$\langle scp \rangle$ Alpha-synuclein $\langle /scp \rangle$ Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. <i>Annals of Neurology</i> , 2020, 88, 503-512.	2.8	78
6	Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. <i>Journal of Experimental Medicine</i> , 2017, 214, 2591-2610.	4.2	72
7	Microcin Amyloid Fibrils A Are Reservoir of Toxic Oligomeric Species. <i>Journal of Biological Chemistry</i> , 2012, 287, 11665-11676.	1.6	62
8	Multiple system atrophy-associated oligodendroglial protein p25 $\hat{1}\pm$ stimulates formation of novel $\hat{1}\pm$ -synuclein strain with enhanced neurodegenerative potential. <i>Acta Neuropathologica</i> , 2021, 142, 87-115.	3.9	55
9	Generation of a humanized $\hat{A}\hat{1}^2$ expressing mouse demonstrating aspects of Alzheimer's disease-like pathology. <i>Nature Communications</i> , 2021, 12, 2421.	5.8	53
10	Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates. <i>Journal of Biomedical Science</i> , 2012, 19, 104.	2.6	52
11	Alpha-synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure. <i>Annals of Neurology</i> , 2021, 89, 1212-1220.	2.8	51
12	Monitoring the Formation of Amyloid Oligomers Using Photoluminescence Anisotropy. <i>Journal of the American Chemical Society</i> , 2019, 141, 15605-15610.	6.6	47
13	Stable activity of a deubiquitylating enzyme (Usp2-cc) in the presence of high concentrations of urea and its application to purify aggregation-prone peptides. <i>Biochemical and Biophysical Research Communications</i> , 2007, 359, 801-805.	1.0	44
14	Increased susceptibility to $\hat{A}\hat{1}^2$ toxicity in neuronal cultures derived from familial Alzheimer's disease (PSEN1-A246E) induced pluripotent stem cells. <i>Neuroscience Letters</i> , 2017, 639, 74-81.	1.0	44
15	Prion-like characteristics of the bacterial protein Microcin E492. <i>Scientific Reports</i> , 2017, 7, 45720.	1.6	28
16	Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. <i>Movement Disorders</i> , 2021, 36, 2444-2446.	2.2	24
17	Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic and Pathological Abnormalities in a Mouse Model of Alzheimer's Disease. <i>Cells</i> , 2021, 10, 1802.	1.8	17
18	Detection of Misfolded $\hat{1}\pm$ -Synuclein Aggregates in Cerebrospinal Fluid by the Protein Misfolding Cyclic Amplification Platform. <i>Methods in Molecular Biology</i> , 2019, 1948, 35-44.	0.4	16

#	ARTICLE	IF	CITATIONS
19	Infusion of blood from mice displaying cerebral amyloidosis accelerates amyloid pathology in animal models of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 213.	2.4	16
20	Amyloid propagation in a sporadic model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045657.	0.4	1
21	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. , 2021, , 291-310.		0